Compounds > moiramide b
Page last updated: 2024-11-12

moiramide b

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

moiramide B: an anti-infective agent that inhibits bacterial acetyl-CoA carboxylase; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11744644
CHEMBL ID181839
CHEBI ID177727
SCHEMBL ID310176
MeSH IDM0469225

Synonyms (9)

Synonym
CHEBI:177727
(2e,4e)-n-[(1s)-3-[[(2s)-3-methyl-1-[(3r,4s)-4-methyl-2,5-dioxopyrrolidin-3-yl]-1-oxobutan-2-yl]amino]-3-oxo-1-phenylpropyl]hexa-2,4-dienamide
moiramide b
CHEMBL181839
SCHEMBL310176
155233-31-1
Q27467819
HY-16943
CS-0012988

Research Excerpts

Overview

Moiramide B is a natural product, broad-spectrum antibiotic that inhibits the carboxyltransferase component of acetyl-CoACarboxylase. It catalyzes the first committed step in fatty acid synthesis.

ExcerptReferenceRelevance
"Moiramide B is a natural product, broad-spectrum antibiotic that inhibits the carboxyltransferase component of acetyl-CoA carboxylase, which catalyzes the first committed step in fatty acid synthesis."( Crystal Structure of Carboxyltransferase from Staphylococcus aureus Bound to the Antibacterial Agent Moiramide B.
Anzalone, N; Neau, DB; Pakhomova, S; Silvers, MA; Silvers, WC; Taylor, CM; Waldrop, GL, 2016)		1.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
organonitrogen compoundAny heteroorganic entity containing at least one carbon-nitrogen bond.
organooxygen compoundAn organochalcogen compound containing at least one carbon-oxygen bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
biotin-carboxyl carrier protein assembly615

Bioassays (24)

Assay IDTitleYearJournalArticle
AID1167360Antibacterial activity against wild type Staphylococcus epidermidis ATCC 35984 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167366Ratio of MPC for Escherichia coli D21 tolC deletion mutant to MIC for Escherichia coli D21 tolC deletion mutant2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167355Antibacterial activity against moiramide-resistant Escherichia coli D21 tolC deletion mutant after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167349Competitive inhibition of Escherichia coli acetyl-CoA carboxylase using acetyl-CoA as substrate in presence of ATP2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167351Antibacterial activity against Pseudomonas aeruginosa PAO1 mexAB/mexCD/mexXY/mexHI/opmH deletion mutant after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167363Selectivity ratio of MIC for moiramide-resistant Staphylococcus aureus ATCC 29213 to MIC for Staphylococcus aureus ATCC 292132014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID247792Inhibitory concentration of the compound against Escherichia coli was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID1167357Antibacterial activity against wild type Staphylococcus aureus ATCC 29213 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167358Antibacterial activity against moiramide-resistant Staphylococcus aureus ATCC 29213 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167350Antibacterial activity against wild type Pseudomonas aeruginosa PAO1 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID245089Minimum inhibitory concentration of the compound againstEscherichia coli Neumann strainwas determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID247897Inhibitory concentration of the compound against Staphylococcus aureus was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID1167346Inhibition of Escherichia coli acetyl-CoA carboxylase2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167361Antibacterial activity against wild type Enterococcus faecalis ATCC 29212 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167362Selectivity ratio of MIC for moiramide-resistant Escherichia coli D21 tolC deletion mutant to MIC for Escherichia coli D21 tolC deletion mutant2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167353Antibacterial activity against Escherichia coli D21 IpxC101 deletion mutant after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167359Antibacterial activity against Staphylococcus aureus ATCC 29213 expressing norA after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167356Antibacterial activity against Escherichia coli D21 IpxC101/tolC deletion mutant after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167354Antibacterial activity against Escherichia coli D21 tolC deletion mutant after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID245074Minimum inhibitory concentration of the compound againstEscherichia coli HN818 strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID1167352Antibacterial activity against wild type Escherichia coli D21 after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID1167367Antibacterial activity against Escherichia coli D21 tolC deletion mutant assessed as mutant prevention concentration after 18 to 24 hrs by two-fold broth microdilution method2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Design, synthesis, and antibacterial properties of dual-ligand inhibitors of acetyl-CoA carboxylase.
AID245102Minimum inhibitory concentration of the compound against Staphylococcus aureus 133 strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
AID245202Minimum inhibitory concentration against Streptococcus pneumoniae G9A strain was determined2005Bioorganic & medicinal chemistry letters, Feb-15, Volume: 15, Issue:4
Pyrrolidinedione derivatives as antibacterial agents with a novel mode of action.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (62.50)29.6817
2010's2 (25.00)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.33 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloramphenicol
Amphenicol: Chloramphenicol and its derivatives.		2.110C-nitro compound;
carboxamide;
diol;
organochlorine compound		antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor
kanamycin a
Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.		2.110kanamycinsbacterial metabolite
phenylalanine
Phenylalanine: An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE.. L-phenylalanine : The L-enantiomer of phenylalanine.. phenylalanine : An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group.		2.0410amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid		algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite
pyrroles
1H-pyrrole : A tautomer of pyrrole that has the double bonds at positions 2 and 4.. pyrrole : A five-membered monocyclic heteroarene comprising one NH and four CH units which forms the parent compound of the pyrrole group of compounds. Its five-membered ring structure has three tautomers. A 'closed class'.. azole : Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen.		2.7230pyrrole;
secondary amine
andrimid
andrimid: a peptide antibiotic; an anti-Bacillus compound in the marine sponge, Hyatella sp.		2.7230
sorbic acid
Sorbic Acid: Mold and yeast inhibitor. Used as a fungistatic agent for foods, especially cheeses.. (2E,4E)-hexa-2,4-dienoic acid : A sorbic acid having trans-double bonds at positions 2 and 4; a food preservative that can induce cutaneous vasodilation and stinging upon topical application to humans. It is the most thermodynamically stable of the four possible geometric isomers possible, as well as the one with the highest antimicrobial activity.. sorbic acid : A hexadienoic acid with double bonds at C-2 and C-4; it has four geometrical isomers, of which the trans,trans-form is naturally occurring.		7.610alpha,beta-unsaturated monocarboxylic acid;
sorbic acid
gentamicin sulfate
[no description available]		2.110
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.110cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials